GlassScriptPhysician profile
Susan Schleith
NPI 1760017826
$7,168.65
in general payments reported to CMS, 2019-2025
18 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,627 · 2022: $2,412 · 2023: $1,965 · 2024: $662 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,129.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,767.90 | 2021-2025 | |
| Alkermes, INC. | $1,286.50 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $706.97 | 2021-2023 | Spravato |
| Neurocrine Biosciences, INC. | $517.27 | 2021-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $510.00 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $432.47 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $383.06 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $325.18 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $321.51 | 2022-2024 | Auvelity, Sunosi |
| Lundbeck LLC | $316.29 | 2021-2023 | Rexulti |
| Corium, LLC | $288.38 | 2023-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $140.44 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $61.44 | 2023-2024 | Qelbree, Qelbree |
| Bausch Health US, LLC | $44.59 | 2022 | |
| Vanda Pharmaceuticals INC. | $19.66 | 2025 | Fanapt, Hetlioz |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $16.54 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $15.70 | 2023 | Quviviq |
| Almatica Pharma LLC | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Schleith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.